Samsung's quiet CardioBand FDA clearance. HealthXL's evidence report.

Issue 014.

Get E&O weekly. | Subscribe | Digital health research from Brian Dolan.

Welcome to E&O.

Last week's newsletter had another sky-high 77 percent open rate. Here's what's happening this week:

Your editor has consumed all articles, videos, reports, interviews and podcasts about AliveCor. I've done my own calls too with some trusted sources. If you might have something to add to this imminent in-depth before it goes live, hit reply to this newsletter and fill me in.
Lilly's broad, multi-year partnership with Evidation, which the two announced late last year, is already leading to published results. This week the two companies announced a project with Apple that used mobile devices and health apps to try to identify mild cognitive issues or mild Alzheimer's. The study used passively collected data from the Apple Watch, Apple Beddit devices, surveys about mood and energy, and

Paying Subscribers Only

It's a good one, too.

This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Samsung’s quiet CardioBand FDA clearance. HealthXL’s evidence report.

Welcome to E&O.

Paying Subscribers Only

Full access to E&O's research and newsletters.

Samsung’s quiet CardioBand FDA clearance. HealthXL’s evidence report.

Welcome to E&O.

Paying Subscribers Only

Full access to E&O's research and newsletters.

New! E&O's free weekly newsletter.